PDCD1 and leukemia: The chimeric antigen receptor T cells engineered with TALENs have been successfully applied to treat leukemia (Leyla’s phenomenon) [13], while autologous tumor-associated T cells treated with CRISPR to knockout programmed cell death protein 1 (PD-1) gene have been recently administered to patients in China to combat lung cancer.